| Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.PMID 39756844 · Lancet Haematol |
2025-Jan |
1 | 1 | 1 | 1 |
质量警告 |
| Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.PMID 39854658 · JCO Precis Oncol |
2025-Jan |
1 | 2 | 2 | 3 |
质量警告 |
| Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial.PMID 39970442 · CA Cancer J Clin |
2025 |
1 | 4 | 4 | 4 |
质量警告 |
| Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors.PMID 41194933 · Front Immunol |
2025 |
2 | 2 | 1 | 3 |
部分完成 |
| Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.PMID 39316666 · Blood |
2024-Dec-26 |
1 | 3 | 3 | 3 |
质量警告 |
| Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.PMID 39715755 · Signal Transduct Target Ther |
2024-Dec-24 |
3 | 5 | 5 | 21 |
质量警告 |
| Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.PMID 39279580 · J Clin Oncol |
2024-Dec-20 |
3 | 4 | 4 | 8 |
提取完成 |
| Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.PMID 39361946 · J Clin Oncol |
2024-Dec-20 |
1 | 1 | 1 | 3 |
质量警告 |
| Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.PMID 39690158 · Signal Transduct Target Ther |
2024-Dec-18 |
1 | 3 | 3 | 6 |
提取完成 |
| Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.PMID 39475359 · Clin Cancer Res |
2024-Dec-02 |
3 | 12 | 12 | 24 |
提取完成 |
| Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.PMID 39480453 · JAMA Oncol |
2024-Dec-01 |
1 | 2 | 2 | 4 |
提取完成 |
| Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.PMID 39173098 · J Clin Oncol |
2024-Dec |
4 | 11 | 11 | 21 |
质量警告 |
| First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048.PMID 39382718 · Int J Clin Oncol |
2024-Dec |
2 | 4 | 4 | 8 |
提取完成 |
| Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.PMID 39631145 · EBioMedicine |
2024-Dec |
3 | 12 | 12 | 21 |
质量警告 |
| Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.PMID 39609425 · Blood Cancer J |
2024-Nov-28 |
3 | 7 | 7 | 20 |
提取完成 |
| Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.PMID 39608979 · J Immunother Cancer |
2024-Nov-27 |
2 | 6 | 6 | 10 |
提取完成 |
| Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial.PMID 39532849 · Signal Transduct Target Ther |
2024-Nov-13 |
1 | 6 | 6 | 12 |
提取完成 |
| Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.PMID 39102624 · J Clin Oncol |
2024-Nov |
2 | 4 | 4 | 12 |
提取完成 |
| Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.PMID 39162872 · Gastric Cancer |
2024-Nov |
3 | 4 | 4 | 4 |
质量警告 |
| SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.PMID 39177931 · Breast Cancer Res Treat |
2024-Nov |
1 | 2 | 2 | 4 |
提取完成 |
| Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.PMID 39237634 · Leukemia |
2024-Nov |
2 | 3 | 3 | 5 |
质量警告 |
| Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.PMID 39284381 · Ann Oncol |
2024-Nov |
2 | 6 | 6 | 12 |
提取完成 |
| Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.PMID 39313594 · Nat Med |
2024-Nov |
5 | 11 | 11 | 30 |
质量警告 |
| Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].PMID 39418883 · ESMO Open |
2024-Nov |
1 | 2 | 2 | 3 |
质量警告 |
| Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.PMID 39082668 · Blood |
2024-Oct-31 |
2 | 6 | 6 | 15 |
质量警告 |
| Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).PMID 39519198 · Int J Mol Sci |
2024-Oct-30 |
1 | 2 | 2 | 3 |
提取完成 |
| Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.PMID 39455094 · J Immunother Cancer |
2024-Oct-24 |
2 | 8 | 8 | 10 |
质量警告 |
| Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.PMID 39442958 · BMJ |
2024-Oct-23 |
1 | 3 | 3 | 6 |
提取完成 |
| Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.PMID 38968156 · Blood Adv |
2024-Oct-22 |
3 | 8 | 8 | 11 |
质量警告 |
| Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.PMID 39413375 · N Engl J Med |
2024-Oct-17 |
1 | 2 | 2 | 4 |
提取完成 |